NCT03325101 2025-06-12Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable MelanomaMayo ClinicPhase 1/2 Terminated7 enrolled 11 charts
NCT01176474 2023-07-19Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV MelanomaH. Lee Moffitt Cancer Center and Research InstitutePhase 1 Completed73 enrolled